Stockscreener 앱 받기
10.73
10.62%
1.03
시장 영업 전:
10.69
-0.04
-0.37%
Kala Bio Inc 주식(KALA)의 최신 뉴스
Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1% - MarketBeat
KALA stock soars to 52-week high, reaching $8.81 - MSN
KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia
ED Attaches ₹79.78 Crore Assets In Sharon Bio-Medicine’s ₹220 Crore Bank Fraud Case - Free Press Journal
Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu
KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale
Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia
Kala Bio's head of research sells $18,662 in stock - Investing.com India
Kala Bio CEO Mark Iwicki sells $44,093 in stock - Investing.com India
Kala Bio's chief business officer sells $15,420 in stock By Investing.com - Investing.com South Africa
Kala Bio’s chief business officer sells $15,420 in stock By Investing.com - Investing.com Nigeria
Kala Bio's head of research sells $18,662 in stock By Investing.com - Investing.com South Africa
Kala Bio CFO Mary Reumuth sells $13,016 in company stock By Investing.com - Investing.com Nigeria
Kala Bio CFO Mary Reumuth sells $13,016 in company stock - Investing.com
Kala Bio's chief business officer sells $15,420 in stock - Investing.com
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus.com
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Australia
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
RBC Capital Downgrades HOOKIPA Pharma (HOOK) - MSN
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Tracking Baker Brothers Portfolio – Q3 2024 Update - Seeking Alpha
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
0.82%
0.53%
자본화:
|
볼륨(24시간):